1. What Is the Radiopharmaceutical Market?
The Radiopharmaceutical Market covers the radioactive drug products used for diagnostic nuclear medicine imaging and therapeutic targeted radionuclide therapy. The products include the technetium-99m labelled diagnostic agents, the gallium-68 and fluorine-18 PET tracers, the lutetium-177 and actinium-225 labelled therapeutic radiopharmaceuticals, and the iodine-131 thyroid cancer ablation therapy. These use the radioactive decay to generate the imaging signal or the cytotoxic radiation dose at the molecular target. The radiopharmaceutical delivers the radionuclide to the specific cell type that expresses the targeted receptor or antigen. Therapeutic radiopharmaceuticals use the PSMA, the somatostatin receptor, the HER2, the fibroblast activation protein, and other tumour-expressed targets to direct the radiation-emitting radionuclide to the tumour cell surface. The high local radiation dose achieves the tumour cell killing that the systemic radiation exposure at the whole-body level limits. The bone marrow, the kidney, and the salivary gland radiation tolerance constraints that dosimetry and the maximum tolerated radiation dose define set the dose ceiling. The radiopharmaceutical market is experiencing the pipeline expansion from the PSMA and SSTR theranostic approvals to the FAP fibroblast activation protein, the HER2, the CEACAM5, and the integrin targets. The next generation of targeted alpha and beta emitter radiopharmaceuticals are advancing these targets through Phase I and II clinical evaluation.
2. Radiopharmaceutical Market Size & Forecast
3. Emerging Technologies
- Lutetium-177 PSMA-617 Pluvicto VISION trial demonstrates the theranostic principle where the PSMA PET imaging with gallium-68 PSMA-11 selects the patients whose tumour metastases show adequate PSMA expression. The lutetium-177 labelled PSMA ligand delivers the cytotoxic beta emission to the same target that the diagnostic PET identified. The precision patient selection enables the therapeutic radiopharmaceutical to benefit only the patients with the PSMA expression that the diagnostic confirms.
- Actinium-225 alpha emitter radiopharmaceutical development uses the high linear energy transfer alpha particles that travel only 50 to 100 micrometres in tissue. The alpha particles deliver 10 to 100 times more energy per track than the beta emitter lutetium-177. The highly localised cellular dose kills the targeted cell without the bystander radiation to the adjacent normal tissue that the longer path length beta emitter distributes more broadly.
- Fibroblast activation protein targeted radiopharmaceutical uses the FAPI fibroblast activation protein inhibitor labelled with lutetium-177 or actinium-225. The FAPI targets the cancer-associated fibroblasts in the tumour stroma that constitutes 80 percent of the pancreatic cancer and other fibrous tumours. The tumour cell itself may express PSMA or SSTR at low levels that limit the direct tumour cell targeting efficacy in these stroma-rich tumours.
- Dosimetry-guided radiopharmaceutical therapy dosing uses the SPECT or PET imaging of the lutetium-177 emission at multiple time points after the therapeutic injection. The imaging calculates the absorbed radiation dose to the tumour and the organs at risk. The individualised dosing administers the maximum effective tumour dose below the kidney and bone marrow tolerance that the population-based fixed-dose regimen does not personalise to the individual patient.
Similar technologies are also transforming adjacent markets. Learn more in our Prostate Cancer Drug Market.
4. Key Market Opportunity
Meaningful upside in the Radiopharmaceutical market is actinium-225 targeted alpha therapy, where the higher energy and shorter path of alpha emission offer advantages in radioresistant disease and actinium-225 PSMA programmes demonstrate strong early clinical results. Companies with actinium-225 manufacturing capacity and clinical data capture this next-wave radiopharmaceutical opportunity. Additional momentum is centered on radiopharmaceutical expansion beyond prostate cancer into breast, lung, and haematological cancers. As actinium alpha therapy advances and new tumour type programmes launch, the addressable opportunity is expanding from prostate and NET radioligand therapy toward a broad radiopharmaceutical platform across multiple oncology indications.
5. Top Companies in the Radiopharmaceutical Market
The following organisations hold leading positions in the Radiopharmaceutical Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novartis
- Bayer
- AstraZeneca
- Eli Lilly
- Bristol-Myers Squibb
- Lantheus
- Telix Pharmaceuticals
- Curium Pharma
- Jubilant Radiopharma
- Cardinal Health
- ITM Isotopen Technologien
- Aktis Oncology
6. Market Segmentation
The Radiopharmaceutical Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Type | Therapeutic Diagnostic |
| By Isotope | Lutetium-177 Actinium-225 Gallium-68 Fluorine-18 |
| By Indication | Prostate Cancer NET Thyroid Bone Metastasis |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Radiopharmaceutical Market trajectory over the forecast period:
Pluvicto PSMA Theranostic Principle Where Gallium-68 PSMA PET Imaging Selects Patients Whose Tumour PSMA Expression the Lutetium-177 PSMA Ligand Delivers Cytotoxic Beta Emission to Has Established the Theranostic Patient Selection Standard That Maximises Therapeutic Benefit.Novartis's Pluvicto generated over USD 980 million in 2023 revenue in its first full year of commercial availability despite manufacturing capacity constraints that created wait times of six to twelve weeks for patients at launch. The supply chain logistics for lutetium-177 require isotope production at nuclear reactors or cyclotrons, short half-life processing into ready-to-use doses, and same-day or next-day dispensing to treatment centres, creating a complex network that Novartis has expanded through Isotopen Technologien München and AAA radiopharmacy partnerships. The VISION trial's overall survival benefit of 4 months and progression-free survival benefit of 5.3 months in metastatic CRPC established a commercial benchmark for radioligand therapy that Eli Lilly, AstraZeneca, and Bristol-Myers Squibb are racing to match with actinium and lutetium programmes in prostate and other tumour types.
Actinium-225 Alpha Emitter 10 to 100 Times Higher Linear Energy Transfer Than Lutetium-177 Beta in 50 to 100 Micrometre Track Length Is Enabling the Highly Localised Cellular Dose That Targets Tumour Cells Without the Broader Bystander Radiation Distribution of Beta Emitters.Advanced Accelerator Applications and Novartis's Lutathera demonstrated improved progression-free survival versus high-dose octreotide in the NETTER-1 trial, with median PFS not reached versus 8.4 months, establishing targeted radionuclide therapy as the standard of care for progressive midgut NETs expressing SSTR. The commercial learnings from Lutathera's launch , including SSTR2 PET staging requirements, treatment centre qualification, and isotope logistics , provided a direct template for Pluvicto's subsequent PSMA-targeted rollout in prostate cancer. Lutathera's success in neuroendocrine tumours demonstrated that regulatory agencies and payers would accept radioligand therapy data from relatively small registrational trials when the unmet need and biomarker rationale are sufficiently compelling.
Dosimetry-Guided Individualised Radiopharmaceutical Dosing Using SPECT Emission Imaging to Calculate Tumour and Organ-at-Risk Absorbed Dose Is Enabling the Maximum Effective Tumour Dose Below Kidney and Bone Marrow Tolerance That Population-Based Fixed Dosing Cannot Personalise.Actinium-225, bismuth-213, and astatine-211 emit high-linear-energy-transfer alpha particles that deposit all energy within 2-4 cell diameters, creating dense double-strand DNA breaks that tumour cells cannot repair through homologous recombination. Eli Lilly's POINT Biopharma actinium-225-PSMA programme and AstraZeneca's FusionPharma platform are advancing actinium-conjugated antibodies and peptides in prostate, ovarian, and breast cancer with Phase 1-2 data showing meaningful tumour shrinkage. The alpha particle's short path length reduces off-target normal-tissue dose versus lutetium-177 beta therapy, potentially enabling higher injected activity and improving the therapeutic window in indications where lutetium-177 requires conservative dosing to protect kidneys and bone marrow.
For related market intelligence, see the Oncology Drug Market.
8. Segmental Analysis
By type, the diagnostic radiopharmaceutical segment dominated the Radiopharmaceutical Market in 2025, as established PET and SPECT imaging agents from Lantheus, Cardinal Health, and Curium underpinned routine oncology and cardiology imaging, generating the largest unit volume in the category.
By indication, the oncology therapeutic segment is projected to register the highest growth rate through 2034, as Novartis's Pluvicto and Lutathera scale and Eli Lilly, Bristol-Myers Squibb, and AstraZeneca advance actinium and lutetium radioligand programmes that establish targeted radiotherapy as a major cancer treatment modality.
9. Regional Analysis
Regional demand patterns across the Radiopharmaceutical Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Radiopharmaceutical Market in 2025, accounting for approximately 47% of global revenue, attributed to the US as the primary market for Pluvicto and Lutathera and the concentration of Novartis, Bristol-Myers Squibb, and Lantheus commercial operations and radiopharmaceutical manufacturing. Moreover, PSMA PET imaging infrastructure sustaining companion diagnostic demand is most advanced in the US. In addition, alpha therapy clinical development is centred in North America. Regional dominance is due to this combination of commercial launch leadership and manufacturing infrastructure.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Radiopharmaceutical Market through 2034, driven by the large prostate and NET cancer patient populations in Europe with expanding access to lutetium PSMA and DOTATATE therapy and the strong European nuclear medicine infrastructure. The region is also witnessing actinium-225 clinical development advancing. Moreover, gallium-68 PSMA PET diagnostic adoption is growing. The combination of these demand drivers and nuclear medicine expertise positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Radiopharmaceutical Market was valued at USD 8.73 Bn in 2025 and is projected to reach USD 27.06 Bn by 2034, growing at a CAGR of 13.4% over the 2026–2034 forecast period.
The Radiopharmaceutical Market is projected to grow at a CAGR of 13.4% from 2026 to 2034.
North America dominated the Radiopharmaceutical Market in 2025, accounting for approximately 47% of global revenue, attributed to the US as the primary market for Pluvicto and Lutathera and the concentration of Novartis, Bristol-Myers Squibb, and Lantheus commercial operations and radiopharmaceutical manufacturing.
The leading companies in the Radiopharmaceutical Market include Novartis, Bayer, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Lantheus, Telix Pharmaceuticals, Curium Pharma, Jubilant Radiopharma, Cardinal Health, ITM Isotopen Technologien, Aktis Oncology.
Pluvicto psma theranostic principle where gallium-68 psma pet imaging selects patients whose tumour psma expression the lutetium-177 psma ligand delivers cytotoxic beta emission to has established the theranostic patient selection standard that maximises therapeutic benefit.
By type, the diagnostic radiopharmaceutical segment dominated the Radiopharmaceutical Market in 2025, as established PET and SPECT imaging agents from Lantheus, Cardinal Health, and Curium underpinned routine oncology and cardiology imaging, generating the largest unit volume in the category.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.